Patent ID: 11969401
Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method for treating or limiting development of age-related macular degeneration (AMD), comprising administering orally, topically to the eyes, or intranasally, in the evening, to a subject in need thereof an amount effective to treat or limit development of AMD of
(a) a GPR143 receptor agonist selected from the group consisting of L-DOPA, an L-DOPA analogue, and pharmaceutically acceptable salts thereof; and
(b) melatonin, a melatonin analogue selected from the group consisting of ramelteon, agomelatine and tasimelteon, or a pharmaceutically acceptable salt thereof.